Role of Prostate Specific Antigen Density for the Prediction of Radical Therapy Requirement in Localized Prostate Cancer

Journal Title: Üroonkoloji Bülteni - Year 2016, Vol 15, Issue 3

Abstract

Objective: Prostate specific antigen (PSA) PSA density (dPSA) is a PSA derivative used for increasing the accuracy of PSA. dPSA is calculated by dividing the prostate volume measured with transrectal ultrasonography by the total PSA value. In this study, we evaluated the role of dPSA in the prediction of radical therapy requirement in localised prostate cancer. Materials and Methods: A total of 398 patients, who underwent radical prostatectomy in our department, were included in the study. Preoperative data of the patients (demographic data, total PSA, prostate volume, dPSA and tumor percent IE on biopsy) were evaluated retrospectively. D’Amico risk stratification was performed according to the radical prostatectomy pathological examination. Evaluated parameters were compared between low-risk group (Group 1), who were candidates for active surveillance, and intermediate-high-risk group (Group 2) who were candidates for radical therapies. A dPSA cut-off value was investigated for the prediction of radical therapy requirement for patients with ROC curve analysis. Results: Mean age of the patients was similar between the two groups (62.6±6.6 vs. 62.6±58; p=0.999). PSA (8.9±6.9 vs. 5.5±1.5; p<0.05), dPSA (0.19±0.1 vs. 0.08±0.03; p<0.05) and tumor percent on biopsy (40.8±32.6 vs. 10.7±11.7; p<0.05) were significantly higher in Group 2 when compared to Group 1. ROC curve analysis revealed that patients with a dPSA value higher than 0.10 were more likely to have intermediate-high-risk disease according to postoperative the D’Amico risk stratification with 71% sensitivity and 86% specificity (AUC=0.782). Conclusion: As a result, it has been shown that a significant portion of patients with a dPSA level of ≥0.1 was included in the intermediate-high-risk group requiring radical therapies according to the postoperative pathological results. We suggest that predictive models including dPSA would better help decide for active surveillance.

Authors and Affiliations

Ozan Bozkurt, Kaan Çömez, Özgür Gürboğa, Ömer Demir, Güven Aslan, Adil Esen

Keywords

Related Articles

The Presence and Thickness of Pseudocapsule after Partial Nephrectomy in Renal Cell Carcinoma

Objective: In this study, we aimed to evaluate the presence and thickness of pseudocapsule after partial nephrectomy in renal cell carcinoma (RCC) cases. Materials and Methods: A total of 100 patients who were admitted t...

Histopathologic Parameters Accompanying by Incidental Prostate Cancer

Objective: It is known that incidental prostate cancer (IPCa) can be seen in a low possibility for patients who were performed transurethral resection of the prostate (TURP) due to bladder outlet obstruction and/ or pro...

Initial Outcomes and Assessment of the Transperineal Multiparametric-Magnetic Resonance Imaging/Ultrasonography Fusion Biopsy Method in Diagnosing Clinically-significant Prostate Cancer

Objective: In this study, it was aimed to investigate the success of transperineal multiparametric magnetic resonance imaging (mp-MRI)/transrectal ultrasonography (USG) fusion prostate biopsy method in prostate cancer di...

Assessment of the Relationship Between Serum Prostate-Specific Antigen Level and Serum Fasting Glucose, Total Cholesterol and Neutrophil-Lymphocyte Ratio in Men Aged 50-70 Years with Prostate-Specific Antigen Level 0-10 ng/mL without Prostate Cancer Diagnosis

Objective: To evaluate the relationship between serum prostate-specific antigen (PSA) level and total cholesterol, fasting blood glucose, and neutrophil-lymphocyte ratio (NLR) in men without prostate cancer. Materials a...

Download PDF file
  • EP ID EP228298
  • DOI 10.4274/uob.701
  • Views 129
  • Downloads 0

How To Cite

Ozan Bozkurt, Kaan Çömez, Özgür Gürboğa, Ömer Demir, Güven Aslan, Adil Esen (2016). Role of Prostate Specific Antigen Density for the Prediction of Radical Therapy Requirement in Localized Prostate Cancer. Üroonkoloji Bülteni, 15(3), 103-106. https://europub.co.uk/articles/-A-228298